CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Petlife Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Petlife Pharmaceuticals Inc
8033 W Sunset Blvd Ste 867
Phone: (424) 216-6807p:424 216-6807 LOS ANGELES, CA  90046-2401  United States Ticker: PTLFPTLF

This company ceased filing statements with the SEC on 10/16/2019.

Business Summary
PetLife Pharmaceuticals, Inc. is a veterinary pharmaceutical company. The Company specializes in the research, development, sales and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis. The Company has developed and is launching veterinary cancer medications and nutraceuticals, based on the Escozine formula. The Company has rights to formulate, package and market a product line, Vitalzul. Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins and minerals. Vitalzul inhibits blood vessels formation in solid tumors. Escozine has been used in combination with chemotherapy, radiation, hormone therapy and other conventional treatments. As of August 31, 2016, Escozine (for humans) was sold as either a nutraceutical or prescription drug in 40 countries, including the United States.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
2/28/20188/31/2017YesYes--Yes

Industries
SIC Code Description
1000 Metal mining
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secr SebastianSerrell-Watts 53 5/30/2018
Chief Financial Officer BruceNiswander 62
Chief Medical Officer VivekRamana 57

Business Names
Business Name
Aztek Ventures Inc.
Genesis Uranium Corp.
Modern Renewable Technologies, Inc.
9 additional Business Names available in full report.

General Information
Number of Employees: 2 (As of 11/30/2012)
Outstanding Shares: 196,751,735 (As of 2/28/2018)
Shareholders: 110
Stock Exchange: OTC
Federal Tax Id: 331133537


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 31, 2023